Needham & Co reiterates a 'Buy' rating on Cubist Pharmaceuticals (Nasdaq: CBST) and raises price target from $24 to $27.
This article: 143 words
-->

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE